In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew estimates of first-episode psychosis and why standardization matters for early treatment and sustainable payment models.
|Videos|March 18, 2022
- MHE March 2022
- Volume 32
- Issue 3
William Dietz of George Washington University Talks About the Importance of Obesity on COVID-19
Author(s)Briana Contreras
William Dietz, MD, PhD, Professor and Director of Sumner M. Redstone Global Center for Prevention and Wellness at George Washington University, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.
Advertisement
Articles in this issue
over 4 years ago
The Cost Burden of Alzheimer'sover 4 years ago
Frequent and Feared. But Can Dementia Be Avoided?over 4 years ago
Cancer Mortality is Decreasing in the U.S.over 4 years ago
New TEFCA Framework Brings Some Clarity to Interoperability Pushover 4 years ago
Fourth Shot is Recommended for the Immunocompromisedover 4 years ago
New COVID-19 Vaccines are in Late-stage Trialsover 4 years ago
Insurers and COVID-19 TestsAdvertisement
Related to this article
CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid shifting Part D premiums.
Bill Kerr of Avalon Heath Solutions says incorporating Z codes into CPT codes for lab and genetic testing would add needed specificity, reduce waste and possibly head off fraud.
States have to turn that information into medical frailty determinations that are clinically credible, consistent, and workable across large Medicaid populations.
A meta-analysis found steatotic liver disease in 75% of patients with sleep-disordered breathing and that CPAP lowered liver enzymes but not liver fat.
Some predicted that drugmakers might boost launch prices to make up for Medicare drug negotiations shrinking profits. Harvard researchers find no evidence of that happening so far.
State PBM reform accelerates through 2026, with Theresa Carnegie of Mintz unpacking new laws, rebate pass-through, spread pricing bans, and compliance risks.
Only 19.1% of commercially insured patients with first-episode psychosis were adherent to antipsychotics in the year after starting treatment.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: State PBM reform in 2026—What's new since spring
2
CMS defined a path for medical frailty. Now comes the hard part.
3
When the referral isn't the finish line: Making SDOH programs actually close care gaps
4
Billing for lab tests, especially genetic tests, is a mess. Bill Kerr has ideas about how to clean it up.
5